Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Leases (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed Current Leases for 7 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 2.18% to $10.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.9 million through Dec 2025, up 2.18% year-over-year, with the annual reading at $10.9 million for FY2025, 2.18% up from the prior year.
  • Current Leases for Q4 2025 was $10.9 million at Theravance Biopharma, roughly flat from $10.9 million in the prior quarter.
  • The five-year high for Current Leases was $10.9 million in Q4 2025, with the low at $503000.0 in Q4 2021.
  • Average Current Leases over 5 years is $5.7 million, with a median of $4.2 million recorded in 2024.
  • The sharpest move saw Current Leases crashed 94.9% in 2021, then soared 1303.61% in 2023.
  • Over 5 years, Current Leases stood at $503000.0 in 2021, then skyrocketed by 1242.54% to $6.8 million in 2022, then crashed by 41.91% to $3.9 million in 2023, then soared by 173.06% to $10.7 million in 2024, then rose by 2.18% to $10.9 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $10.9 million, $10.9 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.